Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial

Bookmark and Share
Published: 10 Dec 2017
Views: 2346
Prof Peter Hillmen - University of Leeds, Leeds, UK

Prof Hillmen speaks with ecancer at the 2017 ASH annual meeting about the CLARITY trial looking at ibrutinib plus venetoclax in relapsed, refractory CLL

Read the news story and watch the press conference for more. 

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.